Among the whole cohort, 258 (31.1%) had HR+HER2- breast cancer, 312 (37.6%) had HER2+ breast cancer, and 260 (31.3%) had TNBC (Table S1). The gene discussed is ERBB2; the disease is breast carcinoma.